» Articles » PMID: 21270149

N1L is an Ectromelia Virus Virulence Factor and Essential for in Vivo Spread Upon Respiratory Infection

Overview
Journal J Virol
Date 2011 Jan 29
PMID 21270149
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The emergence of zoonotic orthopoxvirus infections and the threat of possible intentional release of pathogenic orthopoxviruses have stimulated renewed interest in understanding orthopoxvirus infections and the resulting diseases. Ectromelia virus (ECTV), the causative agent of mousepox, offers an excellent model system to study an orthopoxvirus infection in its natural host. Here, we investigated the role of the vaccinia virus ortholog N1L in ECTV infection. Respiratory infection of mice with an N1L deletion mutant virus (ECTVΔN1L) demonstrated profound attenuation of the mutant virus, confirming N1 as an orthopoxvirus virulence factor. Upon analysis of virus dissemination in vivo, we observed a striking deficiency of ECTVΔN1L spreading from the lungs to the livers or spleens of infected mice. Investigating the immunological mechanism controlling ECTVΔN1L infection, we found the attenuated phenotype to be unaltered in mice deficient in Toll-like receptor (TLR) or RIG-I-like RNA helicase (RLH) signaling as well as in those missing the type I interferon receptor or lacking B cells. However, in RAG-1(-/-) mice lacking mature B and T cells, ECTVΔN1L regained virulence, as shown by increasing morbidity and virus spread to the liver and spleen. Moreover, T cell depletion experiments revealed that ECTVΔN1L attenuation was reversed only by removing both CD4(+) and CD8(+) T cells, so the presence of either cell subset was still sufficient to control the infection. Thus, the orthopoxvirus virulence factor N1 may allow efficient ECTV infection in mice by interfering with host T cell function.

Citing Articles

Tumor Tropism of DNA Viruses for Oncolytic Virotherapy.

Enow J, Sheikh H, Rahman M Viruses. 2023; 15(11).

PMID: 38005938 PMC: 10675630. DOI: 10.3390/v15112262.


A new oncolytic augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery.

Ahmed J, Chard L, Yuan M, Wang J, Howells A, Li Y J Immunother Cancer. 2020; 8(1).

PMID: 32217766 PMC: 7206973. DOI: 10.1136/jitc-2019-000415.


A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9.

Yuan M, Gao X, Chard L, Ali Z, Ahmed J, Li Y Mol Ther Methods Clin Dev. 2015; 2:15035.

PMID: 26417609 PMC: 4571730. DOI: 10.1038/mtm.2015.35.


Enhancement of CD8(+) T-cell memory by removal of a vaccinia virus nuclear factor-κB inhibitor.

Ren H, Ferguson B, Maluquer de Motes C, Sumner R, Harman L, Smith G Immunology. 2014; 145(1):34-49.

PMID: 25382035 PMC: 4405322. DOI: 10.1111/imm.12422.


Poxviruses and the evolution of host range and virulence.

Haller S, Peng C, McFadden G, Rothenburg S Infect Genet Evol. 2013; 21:15-40.

PMID: 24161410 PMC: 3945082. DOI: 10.1016/j.meegid.2013.10.014.


References
1.
Bowie A, Kiss-Toth E, Symons J, Smith G, Dower S, ONeill L . A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci U S A. 2000; 97(18):10162-7. PMC: 27775. DOI: 10.1073/pnas.160027697. View

2.
Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey D . AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009; 458(7237):514-8. PMC: 2726264. DOI: 10.1038/nature07725. View

3.
Smith V, Alcami A . Expression of secreted cytokine and chemokine inhibitors by ectromelia virus. J Virol. 2000; 74(18):8460-71. PMC: 116357. DOI: 10.1128/jvi.74.18.8460-8471.2000. View

4.
Panchanathan V, Chaudhri G, Karupiah G . Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J Virol. 2006; 80(13):6333-8. PMC: 1488959. DOI: 10.1128/JVI.00115-06. View

5.
Lorenzo M, Galindo I, Blasco R . Construction and isolation of recombinant vaccinia virus using genetic markers. Methods Mol Biol. 2004; 269:15-30. DOI: 10.1385/1-59259-789-0:015. View